Sistema de Manejo de Reflujo LINX®

El siststema de manejo de reflujo LINX® es um procedimento laparoscópico.

 

La disponibilidad de producto en el país está sujeta a disposiciones locales. Favor contactar a su representante local de Johnson & Johnson para más informaciones sobre este tema.

Sistema de Manejo de Reflujo LINX®

Características y Beneficios

  • Tratamiento revolucionario para la enfermidade por refujo

    Tratamiento revolucionario para la enfermidade por refujo

    No require cambio anatómico permante para restaurar la barreira de reflujo* LINX® es anillo flexible de pequenos imanes colocados alrededor del EEI (Esfínter Esofágico inferior) durante um procedimiento minimamente invasivo. La fuerza de los imanes ayuda a mantener el EEI cerrado para evitar el reflujo. Cuando los pacientes tragan alimento sólidos o líquidos, LINX® se abre temporalmente para permitir que éstos pasen hacia el estómago.

  • Procedimiento reproducible, resultados consistentes

    Procedimiento reproducible, resultados consistentes

    Demostró mejora constante de los síntomas demostrada en múltiples estudios El 88% de los pacientes informó  que la molestia de acidez había sido eliminada 5 años después del tratamiento con LINX®. El 85% de los pacientes no tenía dependencia  de la medicación diaria para el reflujo después del tratamiento con LINX §. 99% de los pacientes eliminón la regurgitación a los 5 años.

  • Mejora sostenida el puntaje de calidad de vida relacionada a la salud (HRQL por sus siglas en inglés) a de 5 años

    Mejora sostenida el puntaje de calidad de vida relacionada a la salud (HRQL por sus siglas en inglés) a de 5 años**
     

    Se logró la mejora en el puntage de la GERD-HRQL en el 83%  de los pacientes y in el uso del PPI en el 89% de los pacientes.††  Mejora de la satisfacción del paciente a de 5 años.  El dispositivo mantiene la unión gastroesofágica y la anatomía gástrica normales y conserva la función fisiológica (capacidad de eructar y vomitar) ‡‡ 
    Baja incidencia de efectos secundarios.§§

Recursos del producto

Resources

Sistema de Manejo de Reflujo

Referencias

*Based on a 5-year study observing 100 patients who were implanted with LINX. Bothersome heartburn was 89% at baseline and decreased to 11.9% at 5 years(p<0.001), bothersome regurgitation was 57% at baseline and decreased to 1.2% at 5 years (p<0.001), PPI dependence decreased to 15.3% at 5 years (p<0.001).

† Based on 192 patients who underwent MSA with LINX1 as well as a matched pair analysis in which 47 patients underwent MSA2. 98.1% (p=0.118) and 97.8% of patients, respectively, reported symptom improvement or resolution. In a study of 100 patients implanted with LINX, bothersome heartburn decreased to 11.9% (p<0.001) and bothersome regurgitation decreased to 1.2% (p<0.001).

‡ Based on a 5 year prospective, multi-center, single-arm study observing 100 patients who were implanted with LINX, bothersome heartburn was 89% at baseline and decreased to 11.9% at 5 years. (p<0.001)

§ Ganz R. Edmundowicz S, Taiganides P, et al. Long-term Outcomes of Patients Receiving a Magnetic Sphincter Augmentation Device for Gastroesophageal Reflux. Clin Gastroenterol Hepatol. 2016. 14(5):671-7. Based on a study observing 100 patients who were implanted with LINX, daily use of PPIs  decreased to 15.3% at 5 years. (p<0.001)

¶ Ganz R. Edmundowicz S, Taiganides P, et al. Long-term Outcomes of Patients Receiving a Magnetic Sphincter Augmentation Device for Gastroesophageal Reflux. Clin Gastroenterol Hepatol. 2016. 14(5):671-7. Based on a 5 year prospective, multi-center, single-arm study observing 100 patients who were implanted with LINX, regurgitation was 57% at baseline and decreased to 1.2% at 5 years. (p<0.001)

** Ganz R. Edmundowicz S, Taiganides P, et al. Long-term Outcomes of Patients Receiving a Magnetic Sphincter Augmentation Device for Gastroesophageal Reflux. Clin Gastroenterol Hepatol. 2016. 14(5):671-7. Based on a 5 year prospective, multi-center, single-arm study observing 100 patients who were implanted with LINX, there was a significant improvement in the median GERD-HRQL score at 5 years, as compared with  baseline, both with and without PPI use, 4 vs 11 and 27 respectively (p<0.001).

†† Based on a 5 year prospective, multi-center, single-arm study observing 100 patients who were implanted with LINX, the success criteria for quality of life  (50% reduction in total GERD-HRQL score, and  PPI use 50% reduction) were met. 

‡‡ Reynolds J, Zehetner J, Wu P, et al. Laparoscopic Magnetic Sphincter Augmentation vs Laparoscopic Nissen Fundoplication: A Matched-Pair Analysis of 100 Patients. J American College of Surgeons. 2015. 221(1):123-128. Based on a retrospective analysis of 1-year outcomes of patients undergoing MSA and LNF from June 2010 to June 2013. Matched-pair analysis of 100 patients. More LNF patients were unable to belch (8.5% of MSA and 25.5% of LNF; p= 0.028) or vomit (4.3% of MSA and 21.3% of LNF; p=0.004).

€ Ganz R. Edmundowicz S, Taiganides P, et al. Long-term Outcomes of Patients Receiving a Magnetic Sphincter Augmentation Device for Gastroesophageal Reflux. Clin Gastroenterol Hepatol. 2016. 14(5):671-7. 84 subjects were followed up for 5 years, baseline dissatisfaction was 95% and decreased to 7.1% in year 5 (p < .001). Based on the GERD-HRQL.

§§ Reynolds J, Zehetner J, Wu P, et al. Laparoscopic Magnetic Sphincter Augmentation vs Laparoscopic Nissen Fundoplication: A Matched-Pair Analysis of 100 Patients. J American College of Surgeons. 2015. 221(1):123-128. Based on a retrospective analysis of 1-year outcomes of patients undergoing MSA and LNF from June 2010 to June 2013. Matched-pair analysis of 100 patients. There were no patients with severe gas and bloating in the MSA group compared with 10.6% in the LNF group (p=0.022). 8.5% of MSA patients were unable to belch, compared to 25.5% of LNF patients (p = 0.028). 4.3% of MSA patients were unable to vomit when necessary compared to 21.3% of LNF patients (p = 0.004).